Clinical Value of Serum MiRNA in Patients with Acute Promyelocytic Leukemia

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Apr 11

PMID 35401744

Authors

Bei Zhang

Zhixin Pei

Hongxia Wang

Junjun Bai

Junjie Wang

Yingxin Zhao

Mei Jiang

Huimin Wu

Qinglin Song

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the clinical value of specific miRNA in patients with acute promyelocytic leukemia.

Methods: 129 patients with acute promyelocytic leukemia diagnosed in our hospital from January 2015 to January 2020 were selected as the observation group. At the same time, 74 patients with nonacute promyelocytic leukemia who underwent bone marrow aspiration were included as the control group. The expression levels of miR-126-5p and miR-13, different characteristic parameters, and prognosis were compared between the two groups, and the clinical significance of miR-126-5p and miR-13 in acute promyelocytic leukemia was analyzed.

Results: The expression of miR-126-5p (12.31 ± 2.25 versus 17.30 ± 3.28) and miR-13 (16.05 ± 3.47 versus 21.66 ± 2.18) in the observation group was significantly lower than that in the control group ( < 0.05). The expression level of miR-126-5p was significantly correlated with lactate dehydrogenase level, HGB level, NPM1 mutant type, and complete remission ( < 0.05). The expression level of miR-13 was significantly correlated with HGB level, NPM1 mutant type, and complete remission ( < 0.05). Both expression levels of miR-126-5p and miR-13 were not correlated with sex, age, WBC, PLT, proportion of bone marrow primordial cells, hepatomegaly, splenomegaly, lymph node enlargement, and FLT3-ITD ( > 0.05). Cox multivariate regression analysis showed that peripheral blood WBC, bone marrow blast cell count, and miR-126-5p and miR-13 were prognostic factors in patients with acute promyelocytic leukemia ( < 0.05). The sensitivity, specificity, accuracy, and AUC of serum miR-126-5p prediction were 75.83%, 84.56%, 82.17%, and 0.729, respectively. The sensitivity, specificity, accuracy, and AUC of serum miR-13 prediction were 78.64%, 88.49%, 86.20% and 0.882, respectively.

Conclusion: Serum miR-126-5p and miR-13 are closely related to the prognosis of patients with acute promyelocytic leukemia. Serum miR-126-5p and miR-13 can be used as reliable indexes to predict the prognosis of patients.

References

van Gils N, Verhagen H, Smit L . Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. Exp Hematol. 2017; 52:12-23. DOI: 10.1016/j.exphem.2017.04.007. View

Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View

Haybar H, Shahrabi S, Rezaeeyan H, Jodat H, Saki N . Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia. J Cell Physiol. 2019; 234(9):14500-14506. DOI: 10.1002/jcp.28292. View

Ramos K, Ramos I, Zeng Y, Ramos K . Genetics and epigenetics of pediatric leukemia in the era of precision medicine. F1000Res. 2018; 7. PMC: 6053694. DOI: 10.12688/f1000research.14634.1. View

Li S, Ma Y, Tan Y, Ma X, Zhao M, Chen B . Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment. Cell Death Dis. 2018; 9(6):651. PMC: 5973936. DOI: 10.1038/s41419-018-0699-2. View

Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M . ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75. DOI: 10.1056/NEJMoa023143. View

Bi L, Sun L, Jin Z, Zhang S, Shen Z . MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia. Oncol Lett. 2018; 15(4):5611-5619. PMC: 5840650. DOI: 10.3892/ol.2018.8050. View

Sharifi M, Fasihi-Ramandi M, Sheikhi A, Moridnia A, Saneipour M . Apoptosis induction in acute promyelocytic leukemia cells through upregulation of by miR-182 blockage. Mol Biol Res Commun. 2018; 7(1):25-33. PMC: 5991526. DOI: 10.22099/mbrc.2018.27625.1297. View

Rajewsky N . L(ou)sy miRNA targets?. Nat Struct Mol Biol. 2006; 13(9):754-5. DOI: 10.1038/nsmb0906-754. View

10.

Ghetti M, Vannini I, Storlazzi C, Martinelli G, Simonetti G . Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin. Mol Cancer. 2020; 19(1):69. PMC: 7104523. DOI: 10.1186/s12943-020-01187-5. View

11.

Bai Y, Chen C, Guo X, Ding T, Yang X, Yu J . miR-638 in circulating leukaemia cells as a non-invasive biomarker in diagnosis, treatment response and MRD surveillance of acute promyelocytic leukaemia. Cancer Biomark. 2020; 29(1):125-137. DOI: 10.3233/CBM-190899. View

12.

Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, cermak J . Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet. 2010; 19(3):313-9. PMC: 3061996. DOI: 10.1038/ejhg.2010.209. View

13.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

14.

Jakovljevic K, Joksovic M, Matic I, Petrovic N, Stanojkovic T, Sladic D . Novel 1,3,4-thiadiazole-chalcone hybrids containing catechol moiety: synthesis, antioxidant activity, cytotoxicity and DNA interaction studies. Medchemcomm. 2018; 9(10):1679-1697. PMC: 6195102. DOI: 10.1039/c8md00316e. View

15.

Liu J, He P, Pan D . [MiR-218 Targeting Bmi-1 Inhibits Proliferation of Acute Promyelocytic Leukemia Cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020; 28(3):815-820. DOI: 10.19746/j.cnki.issn.1009-2137.2020.03.016. View

16.

Wang Q, Feng T, Xu J, Miao M, Ji X, Zhu H . Low expression of microRNA-340 confers adverse clinical outcome in patients with acute myeloid leukemia. J Cell Physiol. 2018; 234(4):4200-4205. DOI: 10.1002/jcp.27178. View

17.

Xiao H, Liang S, Wang L . Competing endogenous RNA regulation in hematologic malignancies. Clin Chim Acta. 2020; 509:108-116. DOI: 10.1016/j.cca.2020.05.045. View

18.

Wang Z, Fang Z, Lu R, Zhao H, Gong T, Liu D . MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide. Oncol Res. 2019; 27(9):1035-1042. PMC: 7848422. DOI: 10.3727/096504019X15528367532612. View

19.

Shabestari R, Alikarami F, Bashash D, Paridar M, Safa M . Overexpression of MiR-138 Inhibits Cell Growth and Induces Caspase-mediated Apoptosis in Acute Promyelocytic Leukemia Cell Line. Int J Mol Cell Med. 2018; 7(1):24-31. PMC: 6134423. DOI: 10.22088/IJMCM.BUMS.7.1.24. View

20.

Weiss C, Ito K . microRNA-22 promotes megakaryocyte differentiation through repression of its target, . Blood Adv. 2019; 3(1):33-46. PMC: 6325298. DOI: 10.1182/bloodadvances.2018023804. View